BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Bogdana Schmidt
Is there any patient population or anything, just knowing, obviously, cross-trial comparisons are so fraught with so many problems, but is there any patient population for whom you might say, maybe nivolumab, we have slightly better data for? Or do you feel like the dosing schedule of Pembro kind of trumps things?
0
💬
0
Comments
Log in to comment.
There are no comments yet.